Foundations Investment Advisors LLC Has $1.41 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Foundations Investment Advisors LLC lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 2.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,934 shares of the medical research company’s stock after purchasing an additional 141 shares during the period. Foundations Investment Advisors LLC’s holdings in IQVIA were worth $1,406,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Canada Pension Plan Investment Board lifted its position in IQVIA by 6.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after acquiring an additional 211,653 shares during the last quarter. Lazard Asset Management LLC lifted its position in IQVIA by 0.9% during the 1st quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock worth $825,416,000 after acquiring an additional 30,014 shares during the last quarter. Farallon Capital Management LLC lifted its position in IQVIA by 3.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after acquiring an additional 86,870 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in IQVIA by 3.8% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock worth $634,927,000 after acquiring an additional 92,293 shares during the last quarter. Finally, Capital Research Global Investors lifted its position in IQVIA by 7.2% during the 1st quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock worth $540,882,000 after acquiring an additional 143,533 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of research analyst reports. Jefferies Financial Group lowered shares of IQVIA from a “buy” rating to a “hold” rating and cut their target price for the stock from $266.00 to $242.00 in a research report on Wednesday, July 24th. Redburn Atlantic assumed coverage on shares of IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective on the stock. Robert W. Baird boosted their price objective on shares of IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a report on Friday, September 20th. Evercore ISI dropped their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Tuesday. Five research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $267.27.

IQVIA Price Performance

NYSE:IQV opened at $228.31 on Thursday. The firm has a market cap of $41.62 billion, a PE ratio of 29.65, a price-to-earnings-growth ratio of 2.26 and a beta of 1.49. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The company’s 50-day moving average price is $238.71 and its two-hundred day moving average price is $230.92.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The firm had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.22 earnings per share. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.